1.09
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.9001
Aprire:
$0.9295
Volume 24 ore:
12.13M
Relative Volume:
4.03
Capitalizzazione di mercato:
$112.63M
Reddito:
$65,300
Utile/perdita netta:
$-84.93M
Rapporto P/E:
-0.6382
EPS:
-1.708
Flusso di cassa netto:
$-83.57M
1 W Prestazione:
+63.17%
1M Prestazione:
-6.03%
6M Prestazione:
-32.30%
1 anno Prestazione:
-32.72%
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Nome
Inovio Pharmaceuticals Inc
Settore
Industria
Telefono
(858) 410-3134
Indirizzo
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
INO
Inovio Pharmaceuticals Inc
|
1.09 | 79.56M | 65,300 | -84.93M | -83.57M | -1.708 |
|
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-09 | Iniziato | Piper Sandler | Overweight |
| 2024-05-14 | Iniziato | Stephens | Overweight |
| 2024-01-25 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-11-09 | Downgrade | Maxim Group | Buy → Hold |
| 2022-11-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-19 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2021-12-29 | Ripresa | Jefferies | Hold |
| 2021-09-10 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-24 | Iniziato | Jefferies | Hold |
| 2021-03-23 | Iniziato | BofA Securities | Neutral |
| 2021-02-12 | Iniziato | Oppenheimer | Outperform |
| 2020-11-17 | Downgrade | ROTH Capital | Neutral → Sell |
| 2020-11-10 | Aggiornamento | ROTH Capital | Sell → Neutral |
| 2020-09-28 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-01 | Downgrade | Maxim Group | Buy → Hold |
| 2020-07-01 | Downgrade | ROTH Capital | Neutral → Sell |
| 2020-06-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | Downgrade | Stifel | Buy → Hold |
| 2020-05-21 | Iniziato | The Benchmark Company | Buy |
| 2020-04-30 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-03-13 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | Iniziato | ROTH Capital | Buy |
| 2018-02-15 | Reiterato | Maxim Group | Buy |
| 2017-10-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-09-06 | Iniziato | Citigroup | Buy |
| 2017-06-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | Reiterato | Maxim Group | Buy |
| 2017-03-16 | Aggiornamento | Maxim Group | Hold → Buy |
| 2017-03-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
Mostra tutto
Inovio Pharmaceuticals Inc Borsa (INO) Ultime notizie
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - marketwatch.com
HC Wainwright Issues Negative Estimate for INO Earnings - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to Strong-Buy at Zacks Research - MarketBeat
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
INO Upgraded by Jefferies -- Price Target Raised to $3.00 - GuruFocus
Piper Sandler Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
H.C. Wainwright reiterates Neutral on Inovio stock, $2.50 target By Investing.com - Investing.com Canada
Inovio Q2 2026 slides: INO-3107 on track for Oct FDA decision - Investing.com Nigeria
Jefferies upgrades Inovio stock rating on FDA review progress By Investing.com - Investing.com Canada
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO): What Does the Latest Update Mean for Regulatory Progress? - Kalkine Media
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ... - Yahoo Finance
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlig - GuruFocus
Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Inovio Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:INO) 2026-08-12 - Seeking Alpha
Inovio (INO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Inovio Pharmaceuticals, Inc. (INO) stock price, news, quote and history - Yahoo Finance UK
Inovio Q2 EPS $(0.07) beats $(0.22) estimate; loss narrows 74% - scanx.trade
Inovio Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Earnings call transcript: Inovio narrows Q2 2026 loss as INO-3107 nears FDA date - Investing.com
Inovio Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Inovio: Q2 Earnings Snapshot - marketscreener.com
BRIEF-Inovio Pharmaceuticals Q2 Operating Expenses USD 18.6 Million - TradingView
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights - PR Newswire
Adage Capital (INO) discloses 3.43M Inovio shares via warrants in 13G/A - Stock Titan
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - AOL.com
Inovio Pharmaceuticals (NASDAQ:INO): What Could Today’s pipeline focus and funding discipline Update Reveal? - Kalkine Media
Inovio Pharmaceuticals Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Inovio Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Q1 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
RA Capital reports 10.67M-share Inovio (NASDAQ: INO) stake capped at 9.99% - Stock Titan
Inovio Pharmaceuticals, Inc. Share Price Live Today – NASDAQ:INO Stock Price, Chart, News, History - Upstox
Inovio Pharmaceuticals (INO.US) will release its earnings report after market close on August 12. - Moomoo
FMR LLC (INO) discloses 8.45M Inovio shares, including major fund holder - Stock Titan
Inovio Pharmaceuticals (INO) Projected to Release Earnings on Wednesday - MarketBeat
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - marketwatch.com
INOVIO to Report Second Quarter Financial Results on August 12, 2026 - Moomoo
INO Reiterates by Piper Sandler -- Price Target Lowers to $4.00 - GuruFocus
Piper Sandler Reiterates "Overweight" Rating for Inovio Pharmaceuticals (NASDAQ:INO) - MarketBeat
Inovio Pharmaceuticals Inc : Piper Sandler Cu - moomoo.com
Inovio proposes underwritten public offering of common stock, warrants - Bitget
Vanguard Capital Management (INO) discloses 5.05% beneficial stake in Inovio stock - Stock Titan
Form 424B5 Inovio Pharmaceuticals Inc For: 30 July By Investing.com - Investing.com UK
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio Stock Falls 21% After Hours: Here's What's Going On - Benzinga
Inovio prices $20M stock offering, its second raise in quick succession - Dealroom
Inovio prices $20 million public offering of stock and warrants By Investing.com - Investing.com South Africa
Inovio Announces Pricing of $20.0 Million Pub - moomoo.com
Inovio Pharmaceuticals Inc Azioni (INO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):